Mobile

A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infecti...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006410-15

A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the ability of RSV604 to significantly reduce nasopharyngeal viral load during 5 days of intravenous therapy compared with placebo in immunocompromised adult patients with evidence of RSV infection. To determine the safety and tolerability of RSV604 when administered intravenously in immunocompromised adult patients with RSV infection.

Critère d'inclusion

  • Respiratory Syncytial Virus (RSV) Infection

Liens